G-protein-coupled receptors and melanoma.

Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60

Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS One (2011) 1.09

Roles of endothelin signaling in melanocyte development and melanoma. Pigment Cell Melanoma Res (2010) 1.03

Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res (2011) 1.01

Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol (2010) 0.95

U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo. Mol Ther Nucleic Acids (2013) 0.81

The regulation of β-adrenergic receptor-mediated PKA activation by substrate stiffness via microtubule dynamics in human MSCs. Biomaterials (2014) 0.77

Exosomes: The Link between GPCR Activation and Metastatic Potential? Front Genet (2016) 0.76

Ultraviolet radiation and the slug transcription factor induce proinflammatory and immunomodulatory mediator expression in melanocytes. J Skin Cancer (2012) 0.75

Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection. Front Genet (2016) 0.75

Identification of Three Novel Splicing Variants and Expression Analysis of Chicken GPR1 Gene. Biomed Res Int (2017) 0.75

BNGR-A25L and -A27 are two functional G protein-coupled receptors for CAPA periviscerokinin neuropeptides in the silkworm, Bombyx mori. J Biol Chem (2017) 0.75

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Inflammation and cancer. Nature (2002) 53.78

Inflammation and cancer: back to Virchow? Lancet (2001) 27.40

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51

Wnt signalling in stem cells and cancer. Nature (2005) 19.26

Wnt signaling and cancer. Genes Dev (2000) 18.53

Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49

Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53

NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14

Seven-transmembrane receptors. Nat Rev Mol Cell Biol (2002) 11.50

Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27

Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol (1997) 10.26

High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 7.97

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A (1989) 7.41

International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 7.17

G-protein-coupled receptors and cancer. Nat Rev Cancer (2007) 6.80

The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer (2003) 6.70

Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J (2000) 6.55

G protein pathways. Science (2002) 5.29

Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell (2002) 5.23

The metabotropic glutamate receptors: structure and functions. Neuropharmacology (1995) 5.11

Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol (2004) 5.07

Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet (2000) 4.74

The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70

Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol (2003) 4.70

Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68

Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci (1992) 4.39

Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28

The many faces of G protein signaling. J Biol Chem (1998) 4.23

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03

Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin. FEBS Lett (1988) 3.96

Glutamate release promotes growth of malignant gliomas. Nat Med (2001) 3.67

B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61

Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature (2001) 3.57

G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci (2001) 3.49

Platelet-activating factor and related lipid mediators. Annu Rev Biochem (2000) 3.44

Insights into G protein structure, function, and regulation. Endocr Rev (2003) 3.33

The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 3.24

BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res (2003) 3.21

Wnt signalling required for expansion of neural crest and CNS progenitors. Nature (1997) 3.11

The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell (2001) 3.08

Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res (2000) 2.98

MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84

Glutamate receptor function in learning and memory. Behav Brain Res (2003) 2.72

Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67

Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell (1986) 2.65

Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta (2003) 2.58

Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol (2001) 2.58

Gi protein activation in intact cells involves subunit rearrangement rather than dissociation. Proc Natl Acad Sci U S A (2003) 2.52

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47

Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A (1994) 2.43

Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med (1998) 2.42

High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40

E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36

Glioma cells release excitotoxic concentrations of glutamate. Cancer Res (1999) 2.34

Genetics of hair and skin color. Annu Rev Genet (2003) 2.31

Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol (1999) 2.30

Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis (2007) 2.18

Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res (2002) 2.18

Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem J (2001) 2.17

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17

Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol (2001) 2.16

Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A (1997) 2.12

Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12

Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol (2005) 2.11

Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science (1990) 2.07

Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res (2002) 2.06

Nuclear localization is required for Dishevelled function in Wnt/beta-catenin signaling. J Biol (2005) 2.06

Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol (2006) 2.03

Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res (2000) 2.03

Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci U S A (1991) 2.00

Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science (1989) 1.97

Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev (2005) 1.95

G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc Natl Acad Sci U S A (1991) 1.90

Transgenic mouse model for skin malignant melanoma. Oncogene (1998) 1.90

Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A (2001) 1.88

Cancer: inflammation by remote control. Nature (2005) 1.85

The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet (1996) 1.82

Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res (2007) 1.82

Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron (1992) 1.74

Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J (2000) 1.73

Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat (2007) 1.72

Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol (2002) 1.70

Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients. Neuroepidemiology (2007) 1.69

Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene (2001) 1.68

MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet (2001) 1.67

The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med (2002) 1.66

Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol Ther (2006) 1.62

Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res (2004) 1.60

Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res (2003) 1.60

Specificity of coagulation factor signaling. J Thromb Haemost (2003) 1.59

BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol (2003) 1.59

alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res (2005) 1.58

Malignant melanoma in transgenic mice. Proc Natl Acad Sci U S A (1991) 1.58

CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res (2003) 1.57

Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res (1995) 1.56

c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res (1998) 1.54

Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem (2001) 1.52

Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem (2001) 1.52

Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67

Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res (2007) 1.82

Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal (2005) 1.50

Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res (2008) 1.37

Cloning and characterization of a novel gene, SHPRH, encoding a conserved putative protein with SNF2/helicase and PHD-finger domains from the 6q24 region. Genomics (2003) 1.25

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res (2009) 1.24

Progressive appearance of pigmentation in amelanotic melanoma lesions. Pigment Cell Res (2002) 1.08

Identification and characterization of mouse Rab32 by mRNA and protein expression analysis. Biochim Biophys Acta (2003) 1.07

Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. Bioorg Med Chem (2012) 1.02

Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology (2008) 1.02

Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res (2011) 1.01

Exchange protein directly activated by cyclic AMP increases melanoma cell migration by a Ca2+-dependent mechanism. Cancer Res (2010) 0.98

Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res (2007) 0.97

AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res (2009) 0.95

Glutamatergic signaling in cellular transformation. Pigment Cell Melanoma Res (2012) 0.94

Genetics of melanoma. Front Genet (2013) 0.91

Functional effects of GRM1 suppression in human melanoma cells. Mol Cancer Res (2012) 0.91

Albumin nanoshell encapsulation of near-infrared-excitable rare-Earth nanoparticles enhances biocompatibility and enables targeted cell imaging. Small (2010) 0.91

Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor. Int J Oncol (2005) 0.90

Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung. Cancer Lett (2002) 0.88

Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes. Neuropharmacology (2005) 0.87

Epac1 promotes melanoma metastasis via modification of heparan sulfate. Pigment Cell Melanoma Res (2011) 0.87

Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res (2011) 0.87

Anatomical distribution analysis reveals lack of Langerin+ dermal dendritic cells in footpads and tail of C57BL/6 mice. Exp Dermatol (2014) 0.85

Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med (Berl) (2004) 0.85

Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor. Pigment Cell Melanoma Res (2014) 0.85

Highly pigmented Tg(Grm1) mouse melanoma develops non-pigmented melanoma cells in distant metastases. Exp Dermatol (2012) 0.84

mGlu Receptors and Cancerous Growth. Wiley Interdiscip Rev Membr Transp Signal (2011) 0.84

Loss of heterozygosity and internal tandem duplication mutations of the CBP gene are frequent events in human esophageal squamous cell carcinoma. Clin Cancer Res (2004) 0.83

Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. Adv Healthc Mater (2013) 0.82

Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. PLoS One (2013) 0.81

U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo. Mol Ther Nucleic Acids (2013) 0.81

Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. Cancer Res (2014) 0.80

Epac1 increases migration of endothelial cells and melanoma cells via FGF2-mediated paracrine signaling. Pigment Cell Melanoma Res (2014) 0.80

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells. Breast Cancer Res Treat (2015) 0.80

Gβγ subunits inhibit Epac-induced melanoma cell migration. BMC Cancer (2011) 0.80

From existing therapies to novel targets: a current view on melanoma. Front Biosci (2006) 0.79

Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma. Cancer Immunol Immunother (2012) 0.78

Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy. Pharm Res (2014) 0.78

Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells. Pigment Cell Melanoma Res (2014) 0.77

Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res (2014) 0.77

The current management of brain metastasis in melanoma: a focus on riluzole. Expert Rev Neurother (2015) 0.76

Regulation of mGluR1 expression in human melanocytes and melanoma cells. Biochim Biophys Acta (2012) 0.76

Glutamate receptors: emerging players in melanomagenesis. Pigment Cell Melanoma Res (2011) 0.75